Management of Elevated Eosinophils and Lymphocytes

Initial Diagnostic Evaluation

Assess for symptoms of organ damage, such as cardiac, pulmonary, neurologic, or gastrointestinal damage, as persistent eosinophilia can cause significant end-organ damage, according to the Journal of Infection 1
Evaluate for common non-infectious causes, including allergy, atopy, drug reactions, and autoimmune disorders, as recommended by the Journal of Infection 1
Screen for infectious causes, particularly parasitic infections, which are common causes of eosinophilia in returning travelers and migrants, as stated by the Journal of Infection 1

Complete blood count with differential is a necessary test, as suggested by the National Comprehensive Cancer Network 2
Routine serum chemistries are also recommended, according to the National Comprehensive Cancer Network 2
Urinalysis, 24-h proteinuria or urinary protein-to-creatinine ratio, and inflammatory markers, such as C-reactive protein, should be evaluated, as recommended by Nature Reviews Rheumatology 3
Immunological tests, including ANCA, IgG, IgA, IgM, IgE, and IgG4, should be performed, as stated by Nature Reviews Rheumatology 3

For secondary (reactive) eosinophilia, treat the underlying cause, such as allergies, parasitic infections, or drug reactions, as recommended by the National Comprehensive Cancer Network 2
For parasitic infections, appropriate antiparasitic therapy is recommended, according to the Journal of Infection 1
For myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, test for specific genetic abnormalities, such as PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2, as stated by the American Journal of Hematology 6

Patients with eosinophilia ≥1.5 × 10⁹/L for more than 3 months without evidence of end-organ damage should be referred to a hematologist for further investigation, as recommended by the Journal of Infection 1
The relationship between IgE levels and blood eosinophil counts can provide diagnostic clues, as certain conditions show an inverse relationship between these markers, although this fact is from Praxis Medical Insights, a similar relationship is noted in other sources 7

Periodic assessment of organ function to detect early signs of end-organ damage is necessary, as recommended by the National Comprehensive Cancer Network 2
For patients with myeloid neoplasms, molecular monitoring for minimal residual disease may be appropriate, as stated by the National Comprehensive Cancer Network 4

Overlooking potential organ damage in patients with persistent eosinophilia is a common pitfall, as warned by the Journal of Infection 1
Not testing for specific genetic abnormalities that may predict response to targeted therapies is another pitfall, as noted by the National Comprehensive Cancer Network 4